-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43

Benzinga·05/21/2026 12:35:11
Listen to the news
B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $32 to $43.